Department of Pediatrics, University of California, Irvine, Orange, CA, 92868, USA.
Center for Statistical Consulting, University of California, Irvine, CA, 92697, USA.
Alzheimers Res Ther. 2022 Nov 23;14(1):176. doi: 10.1186/s13195-022-01120-6.
Individuals with Down syndrome (DS) are increasingly eligible for clinical trial intervention, particularly for the treatment or prevention of Alzheimer disease (AD). Yet, little is known about research attitudes that may contribute to decisions regarding clinical trial enrollment for people with DS, a gap which is addressed in the current study.
The Research Attitudes Questionnaire (RAQ) is a brief validated instrument that measures cultural and social factors which influence clinical trial enrollment decisions in the general population. Applied herein to a cohort of 1002 families who have an individual with DS, this survey was carried out through a national registry (DS-Connect). In addition to the RAQ, demographic data were collected.
The response rate to the survey was 49.9%. Respondents were asked to complete demographic information and to respond to the 7 question RAQ. The scores were stratified by a cut point assigned a priori into those more favorable toward research participation vs. those less favorably inclined. Within this sample, nearly 95% self-identified as the primary caretaker for the individual with DS. The RAQ score analyses generally indicated favorable respondent views toward research with particularly high favorability ratings from respondents who had previously participated in research and from those who were older (P = .01 to .001).
This is one of the first formal studies to evaluate research attitudes among relatives of individuals with DS and shows the feasibility of using this approach to answer important questions that will guide trialists developing treatments for AD in DS. Future research will require broadening the racial and ethnic mix of respondents and the role that a standardized assessment of research attitudes will have for clinical trial participation.
唐氏综合征(DS)患者越来越有资格参加临床试验干预,特别是针对阿尔茨海默病(AD)的治疗或预防。然而,对于可能影响 DS 患者参与临床试验决策的研究态度知之甚少,本研究旨在解决这一空白。
研究态度问卷(RAQ)是一种简短的经过验证的工具,用于测量影响一般人群临床试验参与决策的文化和社会因素。本研究将其应用于一个由 1002 个 DS 患者家庭组成的队列中,通过一个全国性的登记处(DS-Connect)进行了这项调查。除了 RAQ 之外,还收集了人口统计学数据。
该调查的回复率为 49.9%。受访者被要求完成人口统计学信息,并对 7 个 RAQ 问题进行回答。根据预先设定的一个切点对分数进行分层,将分数分为对研究参与更有利的和对研究参与不太有利的。在这个样本中,近 95%的人自认为是 DS 患者的主要照顾者。RAQ 评分分析总体上表明受访者对研究的看法较为有利,特别是那些以前参加过研究的受访者和年龄较大的受访者(P=0.01 至 0.001)的评价较高。
这是第一项正式评估 DS 患者亲属研究态度的研究之一,表明使用这种方法来回答将指导为 DS 患者开发 AD 治疗方法的试验人员的重要问题是可行的。未来的研究需要扩大受访者的种族和族裔混合,并确定标准化研究态度评估对临床试验参与的作用。